PROS1 and infection: With extensive in vitro and in vivo studies—now including live SARS-CoV-2—we demonstrated that FXa cleaves S protein into non-S1 and S2 fragments, thus inhibiting infection by SARS-CoV-2 or VSV-SARS-CoV-2.